Startseite Kongressberichte & Archiv ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland

ELCC 2019 - European Lung Cancer Congress | ESMO 10-13 April 2019 Geneva, Switzerland

On behalf of VJONCOLOGY Oncoletter attended the ELCC 2019 and interviewed several experts in the field of lung cancer.

Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro:
1:35
 
TKIs to treat EGFRm-positive NSCLC
Marina Garassino:
2:03
 
 
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex:
1:16
 
 
Prof. Kelly’s overview of the RECaN project
Daniel Kelly:
1:50
 
 
Second-generation ALK inhibitors in ALK-positive NSCLC
Antonio Passaro:
0:42
 
 
Updates from the PROFILE 1001 study
Alice Tsang Shaw:
2:05
 
 
The evolving role of the nurse in cancer therapy
Celia Diez de los Rios:
1:50
 
 
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex:
1:03
 
 
Recent developments in radiotherapy for lung cancer
Françoise Mornex:
1:42
 
 
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro:
0:44
 
 
Challenges in using ALK inhibitors
Nicolas Girard:
1:47
 
 
Treatment sequecing strategies in advanced NSCLC
Martin Reck:
1:14
 
 
PACIFIC trial updates: durvalumab after chemotherapy in NSCLC
Marina Garassino:
1:07
 
 
IMpower150: efficacy outcomes of atezolizumab addition in pre-treated EGFR-mutated NSCLC
Martin Reck:
1:31
 
 
Current treatment landscape for ALK-positive NSCLC
Marina Garassino:
2:21
 
 
NSCLC: a treatment landscape in flux in the checkpoint inhibitor era
Martin Reck:
1:23